Published in Antimicrob Agents Chemother on February 01, 1993
In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother (1997) 3.22
Current perspectives on glycopeptide resistance. Clin Microbiol Rev (1995) 2.99
In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob Agents Chemother (1999) 2.88
Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother (1995) 2.50
Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalis. Antimicrob Agents Chemother (1994) 2.43
Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother (1994) 2.21
In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother (1994) 2.03
In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrob Agents Chemother (1995) 1.85
In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother (1997) 1.76
Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). Antimicrob Agents Chemother (1996) 1.63
Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus. Antimicrob Agents Chemother (1997) 1.55
Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits. Antimicrob Agents Chemother (1995) 1.52
Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219). Antimicrob Agents Chemother (1996) 1.52
In vitro activity of fluoroquinolones against gram-positive bacteria. Drugs (1995) 1.46
In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother (1993) 1.33
Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother (1996) 1.30
Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus. Antimicrob Agents Chemother (1999) 1.29
Evaluation of CP-99,219, a new fluoroquinolone, for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother (1995) 1.21
Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrob Agents Chemother (1998) 1.18
Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections. Antimicrob Agents Chemother (1997) 1.15
Trovafloxacin in combination with vancomycin against penicillin-resistant pneumococci in the rabbit meningitis model. Antimicrob Agents Chemother (1999) 1.13
Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes. Antimicrob Agents Chemother (1997) 1.08
Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections. Antimicrob Agents Chemother (1997) 1.07
Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother (1998) 1.05
Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci. Antimicrob Agents Chemother (1994) 1.04
Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. Antimicrob Agents Chemother (1996) 1.01
In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria. Antimicrob Agents Chemother (1993) 0.94
Penetration of trovafloxacin into cerebrospinal fluid in humans following intravenous infusion of alatrofloxacin. Antimicrob Agents Chemother (1997) 0.94
Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia. Eur J Clin Microbiol Infect Dis (1998) 0.90
Efficacy of trovafloxacin, a new quinolone antibiotic, in experimental staphylococcal endocarditis due to oxacillin-resistant strains. Antimicrob Agents Chemother (1998) 0.89
Postantibiotic effect of trovafloxacin against gram-positive and -negative organisms. Antimicrob Agents Chemother (1998) 0.86
New and future antibiotics in the treatment of acute respiratory tract infections. Thorax (1995) 0.85
Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography. Antimicrob Agents Chemother (1998) 0.84
In vitro extracellular and intracellular activity of two newer and two earlier fluoroquinolones against Listeria monocytogenes. Eur J Clin Microbiol Infect Dis (1997) 0.83
Bactericidal activity of the fluoroquinolone WIN 57273 against high-level gentamicin-resistant Enterococcus faecalis. Antimicrob Agents Chemother (1993) 0.82
Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens. Eur J Clin Microbiol Infect Dis (1998) 0.77
Effect of ethanol on fluoroquinolone efficacy in a rat model of pneumococcal pneumonia. Antimicrob Agents Chemother (2006) 0.76
Trovafloxacin concentrations in airway fluids of patients with severe community-acquired pneumonia. Antimicrob Agents Chemother (2000) 0.75
Quality control limits for dilution and disk diffusion susceptibility tests of trovafloxacin against eight quality control strains. J Clin Microbiol (1998) 0.75
Treatment of enterococcal pyelonephritis with trovafloxacin and rifampin: in vitro-in vivo contrast. Antimicrob Agents Chemother (1998) 0.75
Successful trovafloxacin prophylaxis against experimental streptococcal aortic valve endocarditis. Antimicrob Agents Chemother (2000) 0.75
In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium. Eur J Clin Microbiol Infect Dis (1998) 0.75
Transferable beta-lactamase. A new mechanism for in vitro penicillin resistance in Streptococcus faecalis. J Clin Invest (1983) 5.59
Rapid dissemination of beta-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N Engl J Med (1990) 4.40
In-vitro activity of Sch 29482 in comparison with other oral antibiotics. J Antimicrob Chemother (1982) 3.95
Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob Agents Chemother (1991) 2.26
Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agent. Antimicrob Agents Chemother (1990) 1.71
Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocci. Antimicrob Agents Chemother (1992) 1.52
Comparison of Enterococcus raffinosus with Enterococcus avium on the basis of penicillin susceptibility, penicillin-binding protein analysis, and high-level aminoglycoside resistance. Antimicrob Agents Chemother (1991) 1.35
In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic. Antimicrob Agents Chemother (1985) 7.83
In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother (1984) 7.14
Studies on antibiotic synergism against enterococci. I. Bacteriologic studies. J Lab Clin Med (1971) 6.08
Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet (2001) 5.90
Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother (1990) 5.81
In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob Agents Chemother (1986) 5.30
Species-specific resistance to antimocrobial synergism in Streptococcus faecium and Streptococcus faecalis. J Infect Dis (1979) 4.70
Species identities of enterococci isolated from clinical specimens. J Clin Microbiol (1990) 4.54
Rapid dissemination of beta-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N Engl J Med (1990) 4.40
Antimicrobial-drug resistance. N Engl J Med (1996) 4.07
Infections with Acinetobacter calcoaceticus (Herellea vaginicola): clinical and laboratory studies. Medicine (Baltimore) (1977) 4.05
In-vitro activity of Sch 29482 in comparison with other oral antibiotics. J Antimicrob Chemother (1982) 3.95
Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 in an Enterobacter sp. Antimicrob Agents Chemother (2004) 3.82
Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds. J Antimicrob Chemother (1988) 3.80
Mechanism of resistance to antibiotic synergism in enterococci. J Bacteriol (1971) 3.59
Diphtheroid prosthetic valve endocarditis. A study of clinical features and infecting organisms. Am J Med (1980) 3.59
Synergy of penicillin and gentamicin against Enterococci. J Infect Dis (1971) 3.55
Identification of streptococci: use of lysozyme and Streptomyces albus filtrate in the preparation of extracts for Lancefield grouping. J Clin Microbiol (1975) 3.53
Resistance to six aminoglycosidic aminocyclitol antibiotics among enterococci: prevalence, evolution, and relationship to synergism with penicillin. Antimicrob Agents Chemother (1977) 3.27
Penicillin and gentamicin therapy for enterococcal infections. JAMA (1973) 3.07
Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution. Antimicrob Agents Chemother (1991) 3.00
Salmonella typhimurium resistant to silver nitrate, chloramphenicol, and ampicillin. Lancet (1975) 3.00
Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother (1983) 2.99
Automated identification of gram-positive bacteria. J Clin Microbiol (1982) 2.94
Susceptibility of enterococci and Listeria monocytogenes to N-Formimidoyl thienamycin alone and in combination with an aminoglycoside. Antimicrob Agents Chemother (1981) 2.88
Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob Agents Chemother (1988) 2.83
Penicillin-tobramycin synergism against enterococci: a comparison with penicillin and gentamicin. Antimicrob Agents Chemother (1973) 2.83
Characterization of the extended-spectrum beta-lactamase reference strain, Klebsiella pneumoniae K6 (ATCC 700603), which produces the novel enzyme SHV-18. Antimicrob Agents Chemother (2000) 2.80
Development of a standardized screening method for detection of vancomycin-resistant enterococci. J Clin Microbiol (1994) 2.77
Vancomycin-resistant gram-positive bacteria isolated from human sources. J Clin Microbiol (1988) 2.71
Resistance to beta-lactam antibiotics in Streptococcus faecium. Antimicrob Agents Chemother (1982) 2.68
Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med (1981) 2.68
High-level resistance to gentamicin in clinical isolates of Streptococcus (Enterococcus) faecium. Antimicrob Agents Chemother (1988) 2.59
The enterococcus: "putting the bug in our ears". Ann Intern Med (1987) 2.59
A gene conferring resistance to vancomycin but not teicoplanin in isolates of Enterococcus faecalis and Enterococcus faecium demonstrates homology with vanB, vanA, and vanC genes of enterococci. Antimicrob Agents Chemother (1993) 2.56
Studies on antibiotic syngerism against enterococci. II. Effect of various antibiotics on the uptake of 14 C-labeled streptomycin by enterococci. J Clin Invest (1971) 2.49
Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci. Antimicrob Agents Chemother (1999) 2.49
Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol (1980) 2.48
Aminoglycoside-inactivating enzymes in clinical isolates of Streptococcus faecalis. An explanation for resistance to antibiotic synergism. J Clin Invest (1978) 2.48
Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum beta-lactamases. J Clin Microbiol (1994) 2.47
Clinical, microbiologic and therapeutic aspects of purulent pericarditis. Am J Med (1975) 2.46
Development of interpretive criteria and quality control limits for broth microdilution and disk diffusion antimicrobial susceptibility testing of Streptococcus pneumoniae. J Clin Microbiol (1994) 2.44
Bacteremia with Streptococcus bovis and Streptococcus salivarius: clinical correlates of more accurate identification of isolates. J Clin Microbiol (1989) 2.43
Endocarditis due to group D streptococci. Comparison of disease caused by streptococcus bovis with that produced by the enterococci. Am J Med (1974) 2.39
Antimicrobial synergism--an elusive concept. J Infect Dis (1979) 2.39
Antibiotic synergism against Listeria monocytogenes. Antimicrob Agents Chemother (1972) 2.36
Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrob Agents Chemother (1987) 2.35
Antibiotic combinations: should they be tested? Clin Microbiol Rev (1988) 2.34
In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother (1993) 2.29
Recovery of resistance (R) factors from a drug-free community. Lancet (1969) 2.26
Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother (1996) 2.22
Drug therapy: The newer cephalosporins. N Engl J Med (1976) 2.20
SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains. Antimicrob Agents Chemother (2000) 2.15
Studies on the mechanism of intrinsic resistance to beta-lactam antibiotics in group D streptococci. J Gen Microbiol (1983) 2.10
Antecedents of cardiovascular disease in six Solomon Islands societies. Circulation (1974) 2.08
Prevalence of high-level resistance to aminoglycosides in clinical isolates of enterococci. Antimicrob Agents Chemother (Bethesda) (1970) 2.07
Resistance to gentamicin, tobramycin and amikacin among clinical isolates of bacteria. Am J Med (1977) 2.07
In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620. Antimicrob Agents Chemother (1985) 1.99
In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria. Antimicrob Agents Chemother (1997) 1.96
Efficacy of different beta-lactams against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model. Antimicrob Agents Chemother (1991) 1.94
Resistance to penicillin-streptomycin synergy among clinical isolates of viridans streptococci. Antimicrob Agents Chemother (1983) 1.93
Plasmid-mediated resistance to antibiotic synergism in enterococci. J Clin Invest (1978) 1.90
Susceptibility of clinical isolates of bacteria to cefoxitin and cephalothin. Antimicrob Agents Chemother (1974) 1.86
In vitro activities of two glycylcyclines against gram-positive bacteria. Antimicrob Agents Chemother (1994) 1.82
New vancomycin disk diffusion breakpoints for enterococci. The National Committee for Clinical Laboratory Standards Working Group on Enterococci. J Clin Microbiol (1992) 1.79
Detection of penicillin and extended-spectrum cephalosporin resistance among Streptococcus pneumoniae clinical isolates by use of the E test. J Clin Microbiol (1994) 1.78
Multicenter evaluation of the use of Haemophilus test medium for broth microdilution antimicrobial susceptibility testing of Streptococcus pneumoniae and development of quality control limits. J Clin Microbiol (1992) 1.76
Comparison of Vibrio cholerae O139 with V. cholerae O1 classical and El Tor biotypes. Infect Immun (1994) 1.76
Chromosomally mediated beta-lactamase production and gentamicin resistance in Enterococcus faecalis. Antimicrob Agents Chemother (1991) 1.75
Multiply resistant viridans streptococci: susceptibility to beta-lactam antibiotics and comparison of penicillin-binding protein patterns. Antimicrob Agents Chemother (1983) 1.74
Enterococcal infections in patients treated with moxalactam. Rev Infect Dis (1983) 1.72
Comparative in vitro activity of WIN 57273, a new fluoroquinolone antimicrobial agent. Antimicrob Agents Chemother (1990) 1.71
New cause for false-positive results with the cryptococcal antigen test by latex agglutination. J Clin Microbiol (1985) 1.70
Susceptibility of pneumococci to 14 beta-lactam agents: comparison of strains resistant, intermediate-resistant, and susceptible to penicillin. Antimicrob Agents Chemother (1981) 1.67
Occurrence of Streptococcus milleri among beta-hemolytic streptococci isolated from clinical specimens. J Clin Microbiol (1985) 1.64
Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin. Antimicrob Agents Chemother (1998) 1.63
Patterns and mechanisms of antibiotic resistance. Med Clin North Am (1978) 1.63
Cephalothin prophylaxis in cardiac valve surgery. A prospective, double-blind comparison of two-day and six-day regimens. J Thorac Cardiovasc Surg (1977) 1.60
Identification of Streptococcus bovis and Streptococcus salivarius in clinical laboratories. J Clin Microbiol (1984) 1.60
Effect of protein binding on the activity of penicillins in combination with gentamicin against enterococci. Antimicrob Agents Chemother (1979) 1.60
Multiply high-level-aminoglycoside-resistant enterococci isolated from patients in a university hospital. J Clin Microbiol (1988) 1.58
In vitro activity of BMY-28100, a new oral cephalosporin. Antimicrob Agents Chemother (1987) 1.56
Azlocillin, mezlocillin, and piperacillin: new broad-spectrum penicillins. Ann Intern Med (1982) 1.55
Resistance to cefamandole: a collaborative study of emerging clinical problems. J Infect Dis (1982) 1.54
Absence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant enterococci. Antimicrob Agents Chemother (1992) 1.53
Aminoglycoside-modifying enzymes among clinical isolates of Acinetobacter calcoaceticus subsp. anitratus (Herellea vaginicola): explanation for high-level aminoglycoside resistance. Antimicrob Agents Chemother (1979) 1.52
Treatment of experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob Agents Chemother (1989) 1.47
Comparison of fecal lactoferrin latex agglutination assay and methylene blue microscopy for detection of fecal leukocytes in Clostridium difficile-associated disease. J Clin Microbiol (1994) 1.47
Ribosomal resistance of clinical enterococcal to streptomycin isolates. Antimicrob Agents Chemother (1984) 1.45
Antimicrobial susceptibility of flavobacteria. Antimicrob Agents Chemother (1978) 1.44
In vitro activities in new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother (1996) 1.42